FDA to review Protalix taliglucerase alfa resubmitted NDA
The resubmission was done following the issuing of complete response letter (CRL) by the FDA in February 2011. Taliglucerase alfa is Pfizer‘s proprietary plant cell expressed recombinant form
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.